Company: NCNA
Filing Date: 2025-06-18
Form Type: F-3/A
Source: 0001193125-25-142565
Chunk: 7

Company: NuCana plc
Filing Date: 2025-06-18
Form: F-3/A
Chunk 7
---
2017. Subsequently, we transferred the listing of our ADSs to the Nasdaq Capital Market on November 9, 2023. Our ADSs are traded under the symbol
“NCNA.”

Our principal executive offices are located at 3 Lochside Way, Edinburgh, EH12 9DT, United Kingdom. Our telephone
number at this address is +44 (0)131 357 1111.

2

We maintain a website at www.nucana.comto which we regularly post copies of our press releases as well as additional information about us. The information contained on, or that can be accessed through, our website is not a part of this prospectus. We have included our website address in this prospectus solely as an inactive textual reference. We use our registered trademarks, NuCana ®and Acelarin ®, and our trademark, ProTides TM, in this prospectus. This prospectus also includes trademarks, trade names and service marks that are the property of other organizations. Solely for convenience, trademarks and trade names referred to in this prospectus appear without the ®and ™symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or that the applicable owner will not assert its rights, to these trademarks and trade names. Offerings Under This Prospectus Under this prospectus, we may offer ADSs representing our ordinary shares, various series of debt securities or warrants or rights to purchase any of such securities, either individually or in units, with a total value of up to $150,000,000, from time to time at prices and on terms to be determined by market conditions at the time of the offering. This prospectus provides you with a general description of the securities we may offer. Each time we offer a type or series of securities under this prospectus, we will provide a prospectus supplement that will describe the specific amounts, prices and other important terms of the securities, including, to the extent applicable:

| • |     | designation or classification; |

| • |     | aggregate principal amount or aggregate offering price; |

| • |     | maturity, if applicable; |

| • |     | rates and times of payment of interest or dividends, if any; |

| • |     | redemption, conversion or sinking fund terms, if any; |

| • |     | voting or other rights, if any; and |

| • |     | conversion or exercise prices